Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

• Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)

• Richard Malamut, Chief Medical Officer at Medincell comments:"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia."

Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/

Contacts:

David Heuzé
Head of Corporate and Financial Communications, and ESG
[e-mail] [phone]

Grace Kim
Head of US Financial Strategy IR
[e-mail] [phone]

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
[e-mail] [phone]

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
[e-mail] [phone]